MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

Pacific Biosciences of California Inc

Chiusa

SettoreSettore sanitario

2.21 -4.33

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

2.21

Massimo

2.39

Metriche Chiave

By Trading Economics

Entrata

3.9M

-38M

Vendite

-1.3M

38M

Margine di Profitto

-98.853

Dipendenti

575

EBITDA

3.2M

-32M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+2.13% upside

Dividendi

By Dow Jones

Utili prossimi

12 feb 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-66M

607M

Apertura precedente

6.54

Chiusura precedente

2.21

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Pacific Biosciences of California Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

16 gen 2026, 23:29 UTC

Azioni calde

Stocks to Watch: Atossa Therapeutics, Union Pacific

16 gen 2026, 22:48 UTC

Acquisizioni, Fusioni, Takeovers

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16 gen 2026, 22:43 UTC

Acquisizioni, Fusioni, Takeovers

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16 gen 2026, 22:22 UTC

Acquisizioni, Fusioni, Takeovers

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16 gen 2026, 21:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

16 gen 2026, 21:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Auto & Transport Roundup: Market Talk

16 gen 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

16 gen 2026, 21:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

16 gen 2026, 21:48 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16 gen 2026, 21:41 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16 gen 2026, 21:38 UTC

Acquisizioni, Fusioni, Takeovers

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16 gen 2026, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16 gen 2026, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16 gen 2026, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16 gen 2026, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16 gen 2026, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16 gen 2026, 20:44 UTC

Utili

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16 gen 2026, 20:42 UTC

Discorsi di Mercato

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16 gen 2026, 20:28 UTC

Discorsi di Mercato

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16 gen 2026, 19:12 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16 gen 2026, 18:53 UTC

Discorsi di Mercato

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16 gen 2026, 18:41 UTC

Discorsi di Mercato

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16 gen 2026, 18:31 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16 gen 2026, 17:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

16 gen 2026, 17:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

16 gen 2026, 17:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

16 gen 2026, 17:03 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

16 gen 2026, 17:03 UTC

Discorsi di Mercato

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

16 gen 2026, 16:32 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

16 gen 2026, 16:20 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Pacific Biosciences of California Inc Previsione

Obiettivo di Prezzo

By TipRanks

2.13% in crescita

Previsioni per 12 mesi

Media 2.4 USD  2.13%

Alto 3 USD

Basso 2 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Pacific Biosciences of California Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

5 ratings

3

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

1.13 / N/ASupporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Weak Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
help-icon Live chat